Chirality is a fundamental concept in chemistry and plays a critical role in the design and function of many pharmaceutical drugs and intermediates. A chiral molecule can’t be superimposed on its mirror image. These mirror-image forms are called enantiomers.
Although enantiomers share the same molecular formula and many physical properties (e.g., melting point, solubility), they can behave very differently in biological systems. As a result, the interaction between a drug and its target is highly stereospecific.
A racemic mixture contains equal amounts (50:50) of both enantiomers of a chiral molecule. These mixtures are commonly produced in chemical synthesis. As only one enantiomer is generally biologically active, the second enantiomer is regarded as an impurity and needs to be removed from the final drug product.
In this white paper, Thierry Bonnaud, Veranova Principal Scientist, investigated the resolution of a racemic amine via the crystallization of diastereomeric salts, progressing from screening to large-scale process development. Various resolving agents were screened, with process optimizations leading to high enantiomeric purity.
What you’ll learn in this white paper:
- Understand how diastereomeric salt crystallization separates enantiomers, and why a screening strategy is key to finding an effective resolving agent.
- Recognize the importance of optimizing solid-state properties and crystallization conditions for scalable production.
- Learn how solvate formation and polymorphism affect the selectivity and reproducibility of chiral resolution.
- Apply kinetic control strategies that avoid solid solution formation and raise enantiomeric excess.
- Discover how a scalable, high-yield process was developed, achieving >99.9% chiral purity and replacing
costly chiral chromatographic separation.
Please fill out the form below to access the download
"*" indicates required fields